PRODUCT PIPELINE
The Company's objective is to develop and commercialize innovative therapeutic treatments for disorders of the brain and central nervous system, primarily using gene therapy. Key elements of the Company's strategy are:
Focus resources on development of the Company's core technology. The Company intends to focus its research and development efforts on what it believes are achievable technologies having practical applications. Consequently, the Company expects to initially allocate the majority of its resources and efforts to the development of its first-generation products for the treatment of Parkinson's disease, temporal lobe epilepsy, depression and Huntington's disease.
Focus on central nervous system disorders that are likely to be candidates for gene transfer. To attempt to reduce the technical and commercial risks inherent in the development of new gene therapies, the Company intends to pursue treatments for neurological diseases for which:
- the therapeutic gene function is reasonably well understood and has a physiologic role;
- neurosurgical approaches are already established and standard;
- animal studies, which may include those studies involving non-human primates, have indicated gene transfer technology may be effective in treating disease;
- partial correction of the disease is expected to be clinically proven; and
- clinical testing can be conducted in a relatively small number of patients within a reasonably short time period.
“This study was the first successful randomised, double-blind gene therapy trial for….Parkinson's disease.”
The Lancet Neurology,
March 17, 2011